WebMonomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. Molecular Weight 1334.6 Purity 95% For Research Use Only. NOT FOR CLINICAL USE. Related Products ADC-S-037 Mc-Dexamethasone ADC-S-003 DBCO-PEG4-Ahx-DM1 ADC-S-014 MC-DM1 ADC-S-085 DBCO-PEG4-vc-PAB-MMAD ADC-S-063 MC-Sq … Web其构成结构是由靶向CD30的嵌合抗体IgG1与微管蛋白抑制剂MMAE通过一种蛋白酶敏感连接子Vat-Cit偶联在一起。 该药物主要适用于经典霍奇金淋巴瘤(HL)与间变性大细胞淋巴瘤(sALCL),在我国于2024年被NMPA批准用于治疗复发或难治性sALCL和CD30阳性HL患 …
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for
Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to … See more Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once … See more MMAE has been tested with various monoclonal antibodies (usually forming an antibody-drug conjugate). • targeting … See more • Seattle Genetics • Monomethyl auristatin F See more Webvc-MMAE antibody-drug conjugates (ADCs) consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a protease-labile valine-citrulline (vc) linker. scottie scheffler british open results
What is Monomethyl Auristatin E (MMAE)? - BOC Sci
WebDec 1, 2024 · Small molecule toxin conjugates offer a novel approach to tumor antigen specific targeting, allowing reduced systemic exposures and efficient tumor penetration of cytotoxic payloads, compared to... WebNational Center for Biotechnology Information. 8600 Rockville Pike, Bethesda, MD, 20894 USA. Contact. Policies. FOIA. HHS Vulnerability Disclosure. National Library of Medicine. National Institutes of Health. Department of Health and Human Services. WebJan 1, 2024 · vc-MMAE antibody–drug conjugates (ADCs) consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a protease-labile valine-citrulline (vc) linker. prepscholar university of michigan